Proactive Investors - Run By Investors For Investors

Mediclinic's full year trading in line with expectations except Abu Dhabi

Mediclinic expects a £12mln contribution to full year profit from its stake in Spire Healthcare
Mediclinic owns 74 private hospitals and 40 clinics

Private healthcare group Mediclinic International Plc (LON:MDC) said trading for the 2017 financial year is in line with expectations, apart from its Abu Dhabi business.

The company’s businesses in Switzerland, Southern Africa and Dubai all performed as anticipated.

The Abu Dhabi business, however, underperformed due to regulatory changes and certain business and operational challenges.

Mediclinic bought a group of hospitals in Abu Dhabi in 2015 through a reverse takeover of Al Noor Group Hospitals.

However, difficult trading conditions in Abu Dhabi has led to the merged company’s Middle East full year revenue falling 8% to AED3.1bn.

In the group's two biggest regions, Hirslanden, Switzerland and South Africa, revenues rose 3.5% and 6.8% respectively.

The company’s 29.9% stake in Spire Healthcare Group plc (LON:SPI) has also made a contribution to profits.

Mediclinic expects its share of Spire’s annual £53.6mln to be £12mln after adjusting for the amortisation of intangible assets in the purchase price of the equity investment.

The group, which owns 74 hospitals and 40 clinics, bought its stake in Spire for £432mln in 2015.

Shares rose 4.07% to 766.50p in morning trading. 

View full MDC profile View Profile

Mediclinic International Plc Timeline

Related Articles

woman touching her skin
May 21 2019
Here we take a closer look at Integumen PLC (LON:SKIN), which has developed and digitised an artificial skin
man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use